Predicting cancer risk with affinity-based proteomics

Hepatobiliary cancers, including hepatocellular carcinoma (HCC) and gallbladder cancer (GBC), are strongly linked to chronic inflammation. Recent research using the Olink PEA Technology suggests that circulating immune-related proteins may serve as powerful biomarkers for identifying individuals at risk.

In this session, we’ll discuss findings from large hepatitis B virus (HBV)- and hepatitis C virus (HCV)-positive cohorts, including patients with advanced fibrosis or cirrhosis, highlighting proteins such as ICAM-1, CXCL11, HGF, CFHR5, and SCF, and their associations with cancer risk. We’ll also explore population-specific differences, including inflammatory profiles among women with Mapuche ancestry, offering new insights into risk stratification for gallbladder cancer.

Join this webinar to:

• Discover how targeted proteomics with Olink’s PEA platform can be utilized to identify novel circulating biomarkers for HCC and GBC risk assessment, guiding more personalized immunotherapy strategies
• Understand how specific immune-related proteins (ICAM-1, HGF, SCF, and others) are associated with HCC risk.
• Explore how immune protein profiles vary across populations and what this means for personalized cancer risk assessment.

Organised in collaboration with